Floatz logo

Sargramostim

Stage IV Rectal Cancer

National Cancer Institute (NCI)protein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Stage IV Rectal Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
Fudan University
Phase 2BBB
Cediranib
National Cancer Institute (NCI)
Phase 2BBB
Floxuridine
City of Hope Medical Center
Phase 2BBB
Eniluracil
National Cancer Institute (NCI)
Phase 3BB
Dasatinib
Anne Noonan
Phase 2B

View all 27 →

Same molecule, other indications

Sargramostim is also rated in:

cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →